Comparative Pharmacology
Head-to-head clinical analysis: ADCIRCA versus STAXYN.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ADCIRCA versus STAXYN.
ADCIRCA vs STAXYN
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Phosphodiesterase-5 (PDE5) inhibitor; increases cGMP in pulmonary vascular smooth muscle, leading to vasodilation.
Selective inhibitor of cyclic guanosine monophosphate (cGMP)-specific phosphodiesterase type 5 (PDE5). By inhibiting PDE5, sildenafil increases intracellular cGMP levels in the corpus cavernosum, enhancing the relaxant effect of nitric oxide (NO) on smooth muscle cells, thereby facilitating penile erection in response to sexual stimulation.
10 mg orally three times daily.
10 mg sublingually as needed, 30–60 minutes before sexual activity. Maximum 1 dose per 24 hours.
None Documented
None Documented
Terminal half-life: 10–15 hours in healthy adults; prolonged in hepatic impairment (Child-Pugh B/C: up to 30 hours); clinical context: supports twice-daily dosing
Terminal elimination half-life is approximately 4-5 hours; clinically, no accumulation with once-daily dosing
Renal: ~70% (metabolites and unchanged drug), Fecal: ~20%, Biliary: minor
Renal (approximately 90% as metabolites, <2% unchanged); fecal (10%)
Category C
Category C
PDE5 Inhibitor
PDE5 Inhibitor